ArticleAME case reports2026
Carina™ modular robotic-assisted left lower lobectomy after neoadjuvant chemoimmunotherapy for stage IIIA squamous cell lung cancer: a case report.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoimmunotherapy has become a standard approach for locally advanced non-small cell lung cancer (NSCLC), enhancing resectability. However, it also increases surgical complexity because of treatment-induced fibrosis-a challenge well addressed by robotic-assisted thoracic surgery (RATS). This report demonstrates the successful application of a modular robotic platform for post-neoadjuvant left lower lobectomy in a patient with stage IIIA squamous NSCLC, highlighting its precision and feasibility in complex oncologic resections. Case Description: A 51-year-old man was diagnosed with squamous cell carcinoma of the left lower lobe (cT2aN2M0) and achieved a partial response following pembrolizumab plus chemotherapy. After completing neoadjuvant chemoimmunotherapy, robot-assisted left lower lobectomy with systematic lymph node dissection was performed using the Carina™ Modular Robotic System (Ronovo Surgical, Shanghai, China) because of anticipated pleural adhesions and the complex anatomical location of enlarged lymph nodes. The robotic platform demonstrated excellent outcomes: 20 mL blood loss, 5-minute docking time, and 141-minute console time. Intraoperatively, severe pleural adhesions were encountered but successfully managed with robotic assistance, enabling complete dissection and safe tumor resection. The patient recovered rapidly, with chest tube removal by postoperative day 5 and discharge on day 7. Pathology revealed a major pathological response (MPR) with negative bronchial margins. Conclusions: This case demonstrates the technical feasibility of the Carina™ system for complex post-neoadjuvant lobectomy in a patient with stage IIIA squamous NSCLC. Acceptable short-term perioperative outcomes were observed despite pleural adhesions and nodal complexity. Further experience and larger studies are needed to evaluate the potential role of this platform in thoracic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.